Promise and Accomplishments of OSHA April 1996 25th Anniversary Robert Reich
“Let me say this as clearly as I can: OSHA is not working to kill jobs; we’re here to stop jobs from killing workers. We are here to ensure that workers have the tools to keep themselves from getting sick and dying in the workplace, and that employers have the information they need to make their workplaces safe.” This quote is from a January 2011 speech by current Assistant Secretary of Labor for OSHA, Dr. David Michaels, Congress in establishing OSHA in 1970, found that personal injuries and illnesses arising out of work situations impose a substantial burden upon, and are a hindrance to, interstate commerce in terms of lost production, wage loss, medical expenses, and disability compensation payments. Congress declares it to be its purpose and policy, through the exercise of its powers to regulate commerce among the several States and with foreign nations and to provide for the general welfare, to assure so far as possible every working man and woman in the Nation safe and healthful working conditions and to preserve our human resources. Dr. Michaels, speaking about OSHA, “Four decades after the signing of the Act, OSHA is making a difference in the lives of millions of workers. Worker deaths in America are down — from perhaps 14000 in 1970 to 4400 in 2009 — in a workforce that has doubled in size. Injuries and illnesses are down — from 10.9 incidents per 100 workers in 1972 to less than 4 per 100 in 2009. Some of this decline was due to the shift of our economy from …
Video Rating: 0 / 5
JVZoo Product Feed
Categories: Videos Tags: april, 1996, anniversary, osha, robert, 25th, reich, promise, accomplishments
Science help please thank you so much ill rate u best i promise!?
Question by : Science help please thank you so much ill rate u best i promise!?
1. All of these are common types of nuclear radiation EXCEPT:
A) gamma rays
B) alpha particles
C) alpha rays
D) beta particles
2. Which of the following will emit beta particles?
A) an excessive amount of electrons
B) an unstable nucleus
C) a nuclear equation
D) a stable neutron
3. What type of nuclear decay represents release of energy, and is not a particle?
A) alpha decay
B) beta decay
C) gamma decay
D) electron decay
4. When radium-226 decays to form radon-222, the radium nucleus emits a(an)
A) alpha particle.
B) beta particle.
C) gamma ray.
D) electron.
5. Which particles are the least penetrating type of nuclear radiation?
A) gamma particles
B) alpha particles
C) beta particles
D) thorium particles
6. What is the process in which an unstable atomic nucleus emits charged particles or energy or both?
A) radioactivity
B) oxidation
C) decomposition
D) magnetism
7. Which of the following statements is NOT true?
A) You are exposed to nuclear radiation every day.
B) Most of the nuclear radiation you are exposed to occurs naturally in the environment.
C) Naturally occurring nuclear radiation is called background radiation.
D) All natural radiation is at a level low enough to be safe.
8. Alpha-emitting substances, such as radon gas, can be a serious health hazard only if
A) they are inhaled or eaten.
B) their radiation strikes the skin.
C) exposure to them is external.
D) none of the above
9. Uranium-238 undergoes alpha decay. Therefore, uranium-238 will
A) remain stable.
B) change into a different element altogether.
C) emit neutral particles and no energy.
D) not be affected at all.
10. What type of radiation is emitted when polonium-212 forms lead-208?
A) an alpha particle
B) a beta particle
C) gamma radiation
D) all of the above
Best answer:
Answer by Zit
I would love to help you out – but this would not be to your advantage – unless you learn what this is all about you NEVER gonna make it. You have to sit down and figure out how to do it on your own . That’s how it works on this planet. Perhaps you are wasting your time where you are and you should look at a career as a mill wright or plumber – they can make a very decent living if they are good at it.
I know you heard it all before that’s just the way it is. BEEN THERE DONE THAT
What do you think? Answer below!
JVZoo Product Feed
Science help please thank you so much ill rate u best i promise!?
Question by : Science help please thank you so much ill rate u best i promise!?
1. All of these are common types of nuclear radiation EXCEPT:
A) gamma rays
B) alpha particles
C) alpha rays
D) beta particles
2. Which of the following will emit beta particles?
A) an excessive amount of electrons
B) an unstable nucleus
C) a nuclear equation
D) a stable neutron
3. What type of nuclear decay represents release of energy, and is not a particle?
A) alpha decay
B) beta decay
C) gamma decay
D) electron decay
4. When radium-226 decays to form radon-222, the radium nucleus emits a(an)
A) alpha particle.
B) beta particle.
C) gamma ray.
D) electron.
5. Which particles are the least penetrating type of nuclear radiation?
A) gamma particles
B) alpha particles
C) beta particles
D) thorium particles
6. What is the process in which an unstable atomic nucleus emits charged particles or energy or both?
A) radioactivity
B) oxidation
C) decomposition
D) magnetism
7. Which of the following statements is NOT true?
A) You are exposed to nuclear radiation every day.
B) Most of the nuclear radiation you are exposed to occurs naturally in the environment.
C) Naturally occurring nuclear radiation is called background radiation.
D) All natural radiation is at a level low enough to be safe.
8. Alpha-emitting substances, such as radon gas, can be a serious health hazard only if
A) they are inhaled or eaten.
B) their radiation strikes the skin.
C) exposure to them is external.
D) none of the above
9. Uranium-238 undergoes alpha decay. Therefore, uranium-238 will
A) remain stable.
B) change into a different element altogether.
C) emit neutral particles and no energy.
D) not be affected at all.
10. What type of radiation is emitted when polonium-212 forms lead-208?
A) an alpha particle
B) a beta particle
C) gamma radiation
D) all of the above
Best answer:
What do you think? Answer below!
JVZoo Product Feed
Science help please thank you so much ill rate u best i promise!?
Question by : Science help please thank you so much ill rate u best i promise!?
1. All of these are common types of nuclear radiation EXCEPT:
A) gamma rays
B) alpha particles
C) alpha rays
D) beta particles
2. Which of the following will emit beta particles?
A) an excessive amount of electrons
B) an unstable nucleus
C) a nuclear equation
D) a stable neutron
3. What type of nuclear decay represents release of energy, and is not a particle?
A) alpha decay
B) beta decay
C) gamma decay
D) electron decay
4. When radium-226 decays to form radon-222, the radium nucleus emits a(an)
A) alpha particle.
B) beta particle.
C) gamma ray.
D) electron.
5. Which particles are the least penetrating type of nuclear radiation?
A) gamma particles
B) alpha particles
C) beta particles
D) thorium particles
6. What is the process in which an unstable atomic nucleus emits charged particles or energy or both?
A) radioactivity
B) oxidation
C) decomposition
D) magnetism
7. Which of the following statements is NOT true?
A) You are exposed to nuclear radiation every day.
B) Most of the nuclear radiation you are exposed to occurs naturally in the environment.
C) Naturally occurring nuclear radiation is called background radiation.
D) All natural radiation is at a level low enough to be safe.
8. Alpha-emitting substances, such as radon gas, can be a serious health hazard only if
A) they are inhaled or eaten.
B) their radiation strikes the skin.
C) exposure to them is external.
D) none of the above
9. Uranium-238 undergoes alpha decay. Therefore, uranium-238 will
A) remain stable.
B) change into a different element altogether.
C) emit neutral particles and no energy.
D) not be affected at all.
10. What type of radiation is emitted when polonium-212 forms lead-208?
A) an alpha particle
B) a beta particle
C) gamma radiation
D) all of the above
Best answer:
Answer by
Fuck answering all that.
Lazy little shit, do it yourself.
Add your own answer in the comments!
JVZoo Product Feed
Q&A: Science help please thank you so much ill rate u best i promise!?
Question by : Science help please thank you so much ill rate u best i promise!?
1. All of these are common types of nuclear radiation EXCEPT:
A) gamma rays
B) alpha particles
C) alpha rays
D) beta particles
2. Which of the following will emit beta particles?
A) an excessive amount of electrons
B) an unstable nucleus
C) a nuclear equation
D) a stable neutron
3. What type of nuclear decay represents release of energy, and is not a particle?
A) alpha decay
B) beta decay
C) gamma decay
D) electron decay
4. When radium-226 decays to form radon-222, the radium nucleus emits a(an)
A) alpha particle.
B) beta particle.
C) gamma ray.
D) electron.
5. Which particles are the least penetrating type of nuclear radiation?
A) gamma particles
B) alpha particles
C) beta particles
D) thorium particles
6. What is the process in which an unstable atomic nucleus emits charged particles or energy or both?
A) radioactivity
B) oxidation
C) decomposition
D) magnetism
7. Which of the following statements is NOT true?
A) You are exposed to nuclear radiation every day.
B) Most of the nuclear radiation you are exposed to occurs naturally in the environment.
C) Naturally occurring nuclear radiation is called background radiation.
D) All natural radiation is at a level low enough to be safe.
8. Alpha-emitting substances, such as radon gas, can be a serious health hazard only if
A) they are inhaled or eaten.
B) their radiation strikes the skin.
C) exposure to them is external.
D) none of the above
9. Uranium-238 undergoes alpha decay. Therefore, uranium-238 will
A) remain stable.
B) change into a different element altogether.
C) emit neutral particles and no energy.
D) not be affected at all.
10. What type of radiation is emitted when polonium-212 forms lead-208?
A) an alpha particle
B) a beta particle
C) gamma radiation
D) all of the above
Best answer:
Answer by Bjorn
This is Yahoo! Answers, not Yahoo! Do My Homework For Me.
If you can’t find the answers to these questions using your textbook, then you are going to have to deal with the consequences.
What do you think? Answer below!
JVZoo Product Feed
Q&A: Why has Obama broken his promise about keeping lobbyists out of his Administration? He has over a dozen?
Question by Lady Laissez Faire: Why has Obama broken his promise about keeping lobbyists out of his Administration? He has over a dozen?
President Obama promised during his campaign that lobbyists “won’t find a job in my White House.”
•Eric Holder, attorney general nominee, was registered to lobby until 2004 on behalf of clients including Global Crossing, a bankrupt telecommunications firm [now confirmed].
•Tom Vilsack, secretary of agriculture nominee, was registered to lobby as recently as last year on behalf of the National Education Association.
•William Lynn, deputy defense secretary nominee, was registered to lobby as recently as last year for defense contractor Raytheon, where he was a top executive.
•William Corr, deputy health and human services secretary nominee, was registered to lobby until last year for the Campaign for Tobacco-Free Kids, a non-profit that pushes to limit tobacco use.
•David Hayes, deputy interior secretary nominee, was registered to lobby until 2006 for clients, including the regional utility San Diego Gas & Electric.
•Mark Patterson, chief of staff to Treasury Secretary Timothy Geithner, was registered to lobby as recently as last year for financial giant Goldman Sachs.
•Ron Klain, chief of staff to Vice President Joe Biden, was registered to lobby until 2005 for clients, including the Coalition for Asbestos Resolution, U.S. Airways, Airborne Express and drug-maker ImClone.
•Mona Sutphen, deputy White House chief of staff, was registered to lobby for clients, including Angliss International in 2003.
•Melody Barnes, domestic policy council director, lobbied in 2003 and 2004 for liberal advocacy groups, including the American Civil Liberties Union, the Leadership Conference on Civil Rights, the American Constitution Society and the Center for Reproductive Rights.
•Cecilia Munoz, White House director of intergovernmental affairs, was a lobbyist as recently as last year for the National Council of La Raza, a Hispanic advocacy group.
•Patrick Gaspard, White House political affairs director, was a lobbyist for the Service Employees International Union.
•Michael Strautmanis, chief of staff to the president’s assistant for intergovernmental relations, lobbied for the American Association of Justice from 2001 until 2005.
Best answer:
Answer by Do your thing
•Obama- YOU LIE!
Televise Obamacare on CSPAN–LIE!
End Bitter Partisanship……. LIE LIE LIE LIE LIE LIE
No Lobbyists………..Bing bing bing. LIE
No earmarks.. LIE
Not to sign bills without first giving the public five days of notice…. LIE
No CIA investigations……. LIE
End Borrowing, spending too much, deficit orgy spending..lie
Open Administration… Lie
No Healthcare to Illegals…… LIE
N. Grigsby (1811-1890):
Inscription on gravestone:.
Through this inscription I wish to enter my dying protest against what is called the Democratic party I have watched it closely since the days of Jackson and know that all the misfortunes of our nation has come to it through this so called party therefore beware of this party of treason.
Add your own answer in the comments!
JVZoo Product Feed
Categories: News Tags: keeping, about, dozen, lobbyists, promise, administration, over, obama, broken
Health: Terra med Alliance News FDA Approved Leukemia Drugs Shows Promise In Ovarian Cancer Cells
Health: Terra med Alliance News FDA Approved Leukemia Drugs Shows Promise In Ovarian Cancer Cells
Article by terra med alliance leukemia org
Terra med Alliance News: The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA’s Jonsson Comprehensive Cancer Center found.Terra med Alliance News: The drug, when paired with a chemotherapy regimen, was even more effective in fighting ovarian cancer in cell lines in which signaling of the Src family kinases, associated with the deadly disease, is activated.The study appears in the Nov. 10, 2009 edition of the British Medical Journal.Ovarian cancer, which will strike 21,600 women this year and kill 15,500, causes more deaths than any other cancer of the female reproductive system. Few effective therapies for ovarian cancer exist, so it would be advantageous for patients if a new drug could be found that fights the cancer, said Gottfried Konecny, an assistant professor of hematology/oncology, a Jonsson Cancer Center researcher and first author of the study.”I think Sprycel could be a potential additional drug for treating patients with Src dependent ovarian cancer,” Konecny said. “It is important to remember that this work is only on cancer cell lines, but it is significant enough that it should be used to justify clinical trials to confirm that women with this type of ovarian cancer could benefit.”Recent gene expression studies have shown that about one-third of women have ovarian cancers with activated Src pathways, so the drug could potentially help 7,000 ovarian cancer patients every year.In this study, the UCLA team tested the drug against 34 ovarian cancer cell lines and they conducted genetic analysis on all cell lines. Through these analyses, the researchers were able to identify genes that predict response to Sprycel. If the work is confirmed in human studies, it may be possible to test patients for Src activation and select those who would respond prior to treatment, personalizing their care.”We were able to identify markers in the pre-clinical setting that would allow us to predict response to Sprycel,” Konecny said. “These may help us in future clinical trials in selecting patients for studies of the drug.”Sprycel is what is known as a “dirty” kinase inhibitor, meaning it inhibits more than one pathway. Konecny said it also inhibits the focal adhesion kinase and ephrin receptor, also associated with ovarian cancer.The next step, Konecny said, would be to test the drug on women with ovarian cancer in a clinical trial. The tissue of responders would then be analyzed to determine if the Src and other pathways were activated. If that is confirmed, it would further prove that Sprycel could be used to fight ovarian cancer. In studies, women would be screened before entering a trial and only those with Src dependent cancers could be enrolled to provide further evidence, Konecny said, much like the studies of the molecularly targeted breast cancer drug Herceptin enrolled only women who had HER-2 positive disease.”Herceptin is different because we knew in advance that the only worked in women with HER-2 amplification,” he said. “In this case, we don’t clearly know that yet. The data reassure us that the drug works where the targets are over-expressed but we need more testing to confirm this.”The tests combining the drug with chemotherapy are significant because chemotherapy currently is the first line treatment for ovarian cancer patients following surgery. Because Sprycel proved to have a synergistic effect when combined with chemotherapy — both made the other work better — it may be possible to add the targeted therapy as a first line treatment if its efficacy is confirmed in future studies, adding a new tool to an oncologist’s arsenal. Adapted from materials provided by University of California – Los Angeles, via EurekAlert!, a service of AAAS.Terra med Alliance is a non-profit organization in the battle against leukemia helps children living with cancer and their families. Our goal is to make sure children battling cancer know they are not alone. For more information please visit http://www.terramedalliance.org. Email at contact@terramedalliance.org
About the Author
Terra med Alliance is a non-profit organization in the battle against leukemia helps children living with cancer and their families. Our goal is to make sure children battling cancer know they are not alone. For more information please visit http://www.terramedalliance.org. Email at contact@terramedalliance.org
JVZoo Product Feed
Categories: Articles Tags: news, leukemia, alliance, health, approved, terra, promise, drugs, cancer, shows
Do you think obama will follow through with his promise?
Question by NuserUame: Do you think obama will follow through with his promise?
Do you think President-elect Obama will keep his word to end the federal raids on medical marijuana patients? Here is a letter I wrote that I will be emailing to him.
This second video is contradicting because he said he doesn’t think people should be allowed to grow their own, but under California law patients are allowed to grow their own marijuana as recommended by their doctors.
I want to know if you think he will end the federal raids and keep his word or do you think he will make no changes to the current war between the states defined law and the federal governments interference?
Here is the letter:
Dear President Obama,
You have said that you will end federal interference with states that have made laws allowing medical use of marijuana but I believe marijuana should be legalized and taxed instead of being a criminal matter.
I have written a plan for legalizing and taxing marijuana, I would ask that you read over
it, and let me know what you think of it. I know you are a busy man and you have many other
important issues to address but this is a very important issue that should have been
addressed a long time ago.
My plan for the legalization and Taxation of marijuana
Introduction:
Our country is 11 trillion dollars in debt, 43% of adults have admitted to trying marijuana
[including you and me] yet billions of dollars of our countries resources are spent every
year arresting and imprisoning Americans like you and I at the taxpayers expense. Marijuana
should be regulated like alcohol and sold in designated privately owned taxed government
permitted stores similar to ABC stores, where adults over 18 or 21 can purchase various
amounts and varieties of marijuana. But the marijuana has to come from somewhere…
Induction of Marijuana:
The marijuana should be grown by privatized companies independently American-owned [non
imported] Or grown personally by the consumer if a taxed tag was paid for each plant with
enforced penalties for untaxed marijuana plants. Non tax paid marijuana plants would be
treated as growing un permitted untaxed tobacco for commercial use or brewing moonshine.
Sale:
Sale would be treated as an alcohol purchase for adults over 18 or 21 in a designated store
similar to an ABC store. All marijuana sales would be taxed as well as when grown.
Use and Restrictions:
Marijuana should be able to be consumed in a designated area such as an equivalent to a bar,
or smoked in ones own home. Users of marijuana should not drive or operate machinery
similarly to alcohol enforcement would be a sobriety test if suspected of driving under the
influence of marijuana.
Outcome:
Marijuana is a multi-trillion dollar a year industry in the united states, and if taxed
would a great source of government income,would help eliminate national debt, fund
government spending and would eliminate the criminal aspect of marijuana buying and selling.
Marijuana is useful for treating medical ailments as well but should not be restricted to
medical use. Cigarettes and Alcohol are completely legal, yet too many drinks or too many
cigarettes will kill you. There has never been one report of a marijuana overdose yet
hundreds of thousands of people die every year from drunk driving,alcohol poisoning, and
cancer from cigarettes and alcohol. Marijuana has been proven not to have any link to lung
cancers or other any other health related problems.
President Obama, please give this some thought and get back to me, when I voted for you- you said that the peoples voice matters- I am speaking my voice and I hope you can hear me out.This is a very brief version of this letter if you would want to know anything else about the aspects of introducing this please let me know.
Best answer:
Answer by Brad A
Hes never going to read that.
Add your own answer in the comments!
JVZoo Product Feed
Better Than Stem Cells? Short Interfering RNA Hold Promise For Dramatic New Treatments
Better Than Stem Cells? Short Interfering RNA Hold Promise For Dramatic New Treatments
Article by John Leavitt, Ph.D.
I rarely give stock advice. The last time I did was in the summer of 1964 when I read in the newspaper that a new company called ComSat was having an IPO in September. I considered this, perhaps naively, a sure thing. Yet being in my first job I had no money to invest. So, I decided to watch this stock with the fantasy of having invested ,000 (,548 in today’s dollars). My plan was to buy at the IPO price of a share and then sell just before the launch of the first commercial communications satellite, just in case the launch failed. The stock rose meteorically from per share to (the launch did not fail), then the stock split and rose again to more than per share. I made about 0,000 from my ,000 fantasy investment, equivalent to .5 million today.
The reason I bring this up is that recently, I was fortunate to attend a small meeting in Boston that focused on developments in the seemingly esoteric field of siRNA or “short interfering RNA” used to silence genes. The promise of this technology has rightfully created a significant buzz in the scientific and investment communities over for the last two to three years. And as I left this meeting, it occurred to me that in the next 10 to 20 years, siRNA, also called “RNAi”, will probably dominate drug development, with many successful drugs currently targeting specific proteins, like Genentech’s Herceptin and Imclone’s Erbitux, being replaced by RNAi-based drugs. Furthermore, many disease-causing proteins thought to be “undrugable”, like the metastatic biomarker L-plastin for colon, breast, melanoma, prostate, and bladder cancer, could now be targeted by RNAi drugs.
Businesses Are Being Built Around siRNA
Andrew Fire, of Stanford, and Craig Mello, at the University of Massachusetts, discovered “gene silencing by double-stranded RNA” in 1998, earning them the 2006 Nobel Prize in Medicine. In 2001 companies started forming around RNAi. One of them, Alnylam Pharmaceuticals filed its S-1 registration with the SEC in February 2004, claiming ,000 in cash assets and creating 3.2 million shares worth 28 cents each. Two years later, Alnylam went public with stock selling at .50 per share after an unprecedented short start-up time. Alnylam’s shares were selling on NASDAQ at around per share in early July after hitting a 52-week high of .46 last December. By December or perhaps early winter, Alnylam will announce the outcome of its Phase II clinical trial on their lead product for treating the infant respiratory disease caused by Respiratory Syncytial Virus (RSV infections). Alnylam has multiple collaborations funded by Merck, and about 20 pipeline products. At the same time Merck bought Sirna Therapeutics, another RNAi company with strong IP for this technology. During the last year, in order to acquire additional RNAi-relevant IP, Hoffmann-La Roche bought 454, Sigma Chemicals bought Proligo, Alnylam bought Ribopharma, Acuity Pharmaceuticals merged with two other companies to form Opko, Dharmacon became part of Thermo-Fisher Scientific, and RXi Pharmaceuticals was spawned by CytRx. Also Pfizer, GlaxoSmithKline, Novartis, Bristol-Myers Squibb, and Abbott Labs have started R&D programs around RNAi.
Santaris Pharma, a Danish company formed in 2003, has a novel method for making and stabilizing RNAi and drug products in Phase II clinical development. Santaris is strategically partnered through licensing agreements with Enzon, a leading clinical research organization that is conducting clinical trials in the U.S. for many Santaris’ drug candidates. Santaris has completed Phase I/II clinical trials in Denmark, France, the U.K. and the U.S. for an RNAi drug for treating chronic lymphocytic leukemia (CLL) and Phase I trials for a second product treating renal and colon carcinoma and multiple myeloma. The CLL product should compete favorably with Genta’s BCL-2 antisense (RNA) product in development for over a decade, through phase III clinical development, and in pre-registration for CLL and malignant melanoma.
As an aside, it’s worth noting that several of these companies are Nerac clients.
How RNAi works
RNAi therapy is not like stem cell therapy, which will take decades to develop. Approval of the first RNAi drugs is expected in three to five years. This is because stem cell therapy is complex and the science is still in its infancy. By contrast RNAi is well developed because of the advanced understanding of genetics and gene expression. In fact RNAi will be used to make stem cell therapy work.
The 1993 discovery of microRNA, a natural mechanism of gene regulation in all cells, accelerated understanding of how RNAi works. SiRNA is an exogenous synthetic version of the natural endogenous microRNA that takes advantage of the cellular machinery that normally processes and mediates the function of microRNA. Micro- or siRNA (RNAi) is targeted to inhibit a specific counterpart transcript (messenger RNA) that serves as a template for synthesis of an individual protein, the natural process of gene expression. RNAi is processed by a ribonuclease enzyme that binds to a larger precursor siRNA. The enzyme processes siRNA into a 21-nucleotide base-pair double stranded molecule. The specificity of RNAi is governed both by its ‘complimentarity’ to a particular messenger RNA nucleic acid sequence and also by a complex of proteins whose function is to mediate the binding of the RNAi to a target sequence on the messenger RNA, usually in the 3′-noncoding region of the messenger RNA. This binding event leads to a shut-down in synthesis of the protein encoded by the messenger RNA (called “knock-down”).
There is currently little mystery about how to design siRNA molecules and synthesize them, as this method is aided by readily available algorithms. In fact, Todd Woolf, CEO & President of RXi Pharmaceuticals, says, “Weeks instead of years to lead compounds.” This finely tunable technique of RNAi knock-down is also currently used in many academic research labs.
Finally, many studies have been completed including Phase I clinical trials that indicate the siRNA is essentially non-toxic. Conventional drugs have always required the balancing of efficacious doses with consideration of the drug’s negative side-effects.
RNAi’s Dramatic Performance in Preclinical Studies
Several companies and labs have shown siRNA conjugated with cholesterol or other lipid carriers will attach to cholesterol carrier proteins in the blood and transport to the liver rather than being excreted. If an siRNA is used that knocks down an enzyme involved in cholesterol production by the liver, then serum cholesterol levels can be diminished in mice by 30 to 40 percent without diminishing the good cholesterol (HDL) levels. The blockbuster statin drugs like Lipitor, which are well known to produce toxic side-effects in the liver, also reduce cholesterol levels in the blood by about 30 to 40 percent. In the mouse model, the cholesterol-reducing effects of one treatment with siRNA lasts three to four weeks.
In a mouse model for intestinal adenomatous polyposis, the mice develop a high density of benign polyps that ultimately block the intestines, subsequently leading to death. In humans, such polyps are precursors to malignant colon cancer. Johannes Fruehauf of Cequent Pharmaceuticals and Harvard Medical School described a novel method for delivering siRNA to the intestinal tract which targeted beta-catenin synthesized by polyp cells. Increased expression of beta-catenin is associated with proliferation of polyp cells but not by itself in the conversion of benign polyps to malignancy. Cequent has demonstrated that bacteria, such as E. coli, carrying about 100 copies of recombinant siRNA in a plasmid vector, can simply be fed to polyposis mice whose intestines are clogged with polyps. Administration of these bacteria containing the siRNA copies killed the polyps and cleared up the problem completely; the histopathology pictures established clearly that the intestines were cleansed of the polyps. The explanation for this efficacy is that thousands of these bacteria were engulfed by the polyp cells by the natural process of endocytosis. The bacteria were dissolved in the endosomes, the plasmids carrying the siRNA insert were fragmented, and the liberated siRNA inhibited beta-catenin synthesis in the polyps. This last step causes the polyps to self-destruct by the natural mechanism of apoptosis, or programmed cell death.
The prospect for siRNA as a therapy seems unlimited in that any and every gene can become a target for this therapy. Before siRNA, many potential disease targets were considered “undrugable,” meaning that virtually every disease can be considered for siRNA therapy, including all forms of cancer, metabolic diseases like diabetes, and cardiovascular disease. One speaker at the meeting predicted that when the first siRNA proved its efficacy in a Phase III clinical trial, this event would lead to an explosion of interest in siRNA by Big Pharma and the investment community. It seems inevitable that this will happen in the not too distant future.
About the Author
Dr. John Leavitt is an analyst for Tolland, Conn.-based Nerac Inc., a research and advisory firm for companies developing innovative products and technologies. He is an expert in the biotechnology fields of diagnosis and treatment of human diseases, genetics, and cell and molecular biology. For information, please visit http://www.nerac.com.
Related Non Small Cell Carcinoma Articles
JVZoo Product Feed
Categories: Articles Tags: promise, , hold, better, interfering, than, treatments, cells, short, stem
*I Promise* A Justin Bieber Love Story Ep. 69
Doctor: So you DONT have lung cancer, but I need to give you this medication to prevent lung cancer because you are showing aigns of preducing cancer. Take this to a pharmisist or a doctor. Writes on a sticky note rips it out and hands it to brittney. And closes his notebook. Have a good day you can go. Grins and walks out of the room. Brittney: Im showing signs of lung cancer? Gets off the table and walks out the door. Justin: Catches up to her and grabs her hand. Brittney: Rushes into his arms and starts crying leaving tear stains on his shirt. Her body shaking from crying so hard. Justin: Holds her tightly and rest his head on the top of her head while stroking her hair. Brittney: pulls away and sniffs. Sorry I got some tears on your shirt. Laughs and wipes her eyes. Justin: Its fine. Wraps his hand around her waist from the side and starts walking to his car. Brittney: Does the same. Justin? Do you think the medicine will work and help stop the preduction of the cancer? Justin: I dont know. All we can do is pray that it will. I just hope my princess doesnt get cancer. Brittney: Smiles. Awww your so sweet. J&B: at justins car. Justin: Standing by the drivers seat across from brittney his hair gently blowing in the wind. Brittney: Looks at him while jerking the car door open and plopping in the passenger seat. Justin: Im gonna to paris tomorrow night for 3 days. Brittney: Okay ill stay with lucie. Have you noticed shes gone all day? Justin: She didnt tell you? Brittney …
JVZoo Product Feed
New Non-Invasive Technology Shows Promise in Shrinking Liver Tumors
New Non-Invasive Technology Shows Promise in Shrinking Liver Tumors
Article by Dashing
In a phase II study, 41 patients with hepatocellular carcinoma (HCC), a liver cancer that often does not respond well to chemotherapy, were treated with very low levels of an electromagnetic field emit from a spoon-like device positioned in the patients’ mouths.
After six months, the tumors in 14 patients had stabilized after each established three one-hour treatment per day each day; the therapy created no momentous side effects. The most successful tumor decrease occurred in a female patient who has established regular therapy since August 2006; her tumor continues to shrink without serious side effects.
Boris Pasche, M.D., Ph.D., executive of the UAB Division of Hematology and Oncology in the Department of Medicine, and collaborators reported their findings Aug. 9, 2011, in the online version of the British Journal of Cancer.
“The very appealing advantage of this novel therapy is its capability to shrink tumors without security damage. This method literally finds cancer cells in the body and block their growth without touching the growth of normal cells,” says Pasche, senior author of the study.
To date, other treatment option have been limited. The U.S. Food and Drug Administration has only approved one drug, sorafenib, in 20 years. Pasche says this drug does prolong life an standard of three months, but it doesn’t make the patient feel better.
“With our treatment, seven of the 11 patients who report pain prior to the start of their treatment reported either a complete disappearance of pain or decreased amount,” says Pasche. Preliminary confirmation also indicates that the treatment not only exaggerated the primary cancer, but also its metastases.
The small battery-driven “radio frequency electromagnetic field producer” has an attached spoon-shaped mouthpiece. The device is programmed and the patient pushes a button to start treatment. It is like a watch in that it emit low levels of amplitude-modulated radio frequency, resulting in the delivery of doses 100 to 1,000 times less than those generated from a cell phone.
“When you take the representative and put it in your mouth the body becomes an antenna — the whole body receives a tiny but fairly homogenous amount of radio-frequency,” Pasche says.
In a 2009 study, Pasche and research partners Alexandre Barbault in France and Frederico Costa at the University of Sao Paulo in Brazil identified tumor-specific frequencies and tested the feasibility of administering such frequencies to patients with advanced cancer. They then decided to settle on whether these frequencies had an effect on the growth of tumors.
Pasche believes this a promising therapy that could be converted into a standard of care in the near future. The therapy is ready for an FDA-registration study and randomized trials, which will be initiate at UAB upon funding being secured for the project.
The technology also is in the beginning stage of being studied in breast cancer patients, by Pasche together with UAB collaborators Andres Forero, M.D., and John Carpenter, M.D.
“Although liver transplant is the most effective treatment, that option will be available for only a fraction of patients. Better therapies are sorely needed for the larger number of HCC patients,” Pasche says.
About the Author
Find More Non Small Cell Carcinoma Articles
JVZoo Product Feed
Categories: Articles Tags: tumors , liver, shows, noninvasive, technology., shrinking, promise
Jim Sokolove – 24 Hour Promise
Attorney Jim Sokolove explains Sokolove Law’s 24 Hour Promise.
Video Rating: 0 / 5
JVZoo Product Feed
Jim Sokolove – 24 Hour Promise
Attorney Jim Sokolove explains Sokolove Law’s 24 Hour Promise.
www.gb.cotoro.com trends – malpractice attorneys new york, mesothelioma clinical trial, mesothelioma types, new york malpractice attorneys, new york medical malpractice attorney, personal injury attorneys nyc, personal injury lawyer denver, asbestos law suit, asbestos attorney washington,…
Video Rating: 0 / 5
JVZoo Product Feed
What is the only thing self-determination can promise us?
Question by KayleeR: What is the only thing self-determination can promise us?
If you believe in yourself, what can you expect? I am doing a paper on determination and I need to find a very good clincher for the end.
The beginning with a hook to catch reader’s attention Belief is clearly stated
Body: Belief is explained and terms defined A story is used to illustrate belief (anecdote, dialogue, personal experience, examples)
Conclusion: Point or meaning of story explained Belief is restated in a new, powerful way
The influence of determination, I believe, can linger in one’s life for many years to come. It strengthens people in the face of adversity and helps them work towards powerful goals despite unexpected obstacles. Once determined, one’s passion remains until the task is accomplished. Even if you believe that you can no longer proceed or withstand, you must still continue with all of your might. I believe determination influences me to perceive what I have the ability to do both now and in the future. When those around you believe you can achieve, you find that you believe so as well.
Determination lingers for a long time because if you are truly determined, you will presume working towards your dreams no matter how far or long it might take to finally make it come true. To firmly hold on to and carry out a belief, plan, or action is determination. It is the vitality of an athlete, the brains of the genius, and the heart of the philanthropist – the greatest strength of each individual that no one can take away from them. I am especially determined to becoming an MD in the fields of radiology and medical research because my uncle died at the age of 50 from lung cancer. I long to make a change by finding a cure and helping those who suffer from similar diseases. Although it would be most difficult, I cannot and will not turn around. When determined, a goal is hard to put down. It clings on to the edge of the heart and though there may be passing storms, it continues to hold on deep inside forever.
I also believe that determination towards a single aspiration is like a tree with a system of roots. It has branches reaching out towards other smaller, yet highly significant goals. For example, the first steps to changing the world might be donating to the local food pantry, joining an environmental organization, visiting a nursing home, and walking in charitable marathons. I think that a vast number of missions can be fulfilled this way deed by deed and person by person. Because determination for success in a paramount ambition leads to the many steps required prior to reaching it, it envelops a person’s whole being and involves their entire life. We are led by determination into a new promised land- our own independent promised land with the promise of
Best answer:
Answer by Darb D
bruce lee wrote….some people are naturally gifted but sometimes intense desire itself can produce great talent…..
Give your answer to this question below!
JVZoo Product Feed
Categories: News Tags: only, thing, selfdetermination, promise
which of the following has the greatest promise as a lung cancer chemotherapy agent? A drug that?
Question by andrew_s_1986: which of the following has the greatest promise as a lung cancer chemotherapy agent? A drug that?
A. causes cells to devide at a right angle from their usual orientation.
B.interferes with cellular meiosis.
C. prevents sister chromatids from separating at anaphase.
D. prevents tetrad formation
E. prevents crossing over.
Best answer:
Answer by Science Geek
Tetrads only form during meiosis, so the previous responder is wrong. The only answer that would possibly make sense is C. If the sister chromatids don’t separate, then the cell cannot divide. Both centrosomes will pull on the centromere, but it won’t move. One side may break its hold on the centromere, but then one new cell would have no DNA and would die, and the other would have too much DNA and would die.
Add your own answer in the comments!
JVZoo Product Feed
which of the following shows the greatest promise as a lung cancer chemotherapy agent?
Question by socsmama: which of the following shows the greatest promise as a lung cancer chemotherapy agent?
A drug that….
A. Causes cells to divide at a right angle from their usual orientation.
B. interferes with cellular meiosis.
C. Prevents sister chromatids from sepratingat anaphase.
D. Prevents tetrad formation.
E. Prevents crossing over.
Best answer:
Answer by Susan S
E. Prevents crossing over.
What do you think? Answer below!
JVZoo Product Feed
Categories: Answers Tags: greatest, agent, following, lung, which of the following shows the greatest promise as a cancer chemotherapy agent, cancer, shows, promise, chemotherapy
Neural stem cells showing promise as treatment for aggressive form of brain cancer, scientists find.(International Pages)(Brief Article): An article from: Transplant News
Neural stem cells showing promise as treatment for aggressive form of brain cancer, scientists find.(International Pages)(Brief Article): An article from: Transplant News
This digital document is an article from Transplant News, published by Transplant Communications, Inc. on April 10, 2000. The length of the article is 492 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details
Title: Neural stem cells showing promise as treatment for aggressive form of brain cancer
List Price: $ 5.95
Price: $ 5.95
JVZoo Product Feed
Categories: Products Tags: aggressive, treatment, cancer, promise, pagesbrief, article, neural, news, from, brain
Experimental Vaccine Made From Frozen Immune Cells Shows Promise For Prostate Cancer Patients
My father has become a foot soldier in the war on cancer
Image by Unhindered by Talent
It’s hard to know how to say this.
"My father is fighting cancer." Nope. Sounds too much like a back alley brawl, and this is a much bigger deal than that.
"My father is battling cancer." Closer. Given the great chunks of medical machinery being brought to bear on his illness, "battle" seems more descriptive than "fight". But battles are (usually) parts of wars, and I’m inclined to be more explicit about that. So…
"My father has become a foot soldier in humanity’s on-going war with cancer."
This seems pretty apt. We (mostly my Mom) are the support staff, providing love and support and matériel, eagerly and nervously awaiting news from the front. But he’s the one in the trenches, dealing with the foot rot and the deafening machines of war and the crap rations.
The key diagnoses were last week, and luckily my wonderful sister was able to fly down from New York and be with them for several days of intense and difficult information gathering. A huge thanks to her for being there for all of us!
Dad’s got cancer of the throat. The doctors place the odds at 50/50, but the system is pretty complex and there are a whole host of things that could slip or crack. He’s got several weeks of radiation and chemo ahead, so it’s going to be a long slog (and probably a rough Christmas), but Dad and Mom and the doctors are all prepared for the fight. Saturday morning was the first skirmish; happily he came through that in excellent shape.
Everyone here in Morris has been really supportive and wonderful, for which we are extremely grateful. We’re going to take off the week of Thanksgiving and will drive down to be with my parents for that week. Until then, it’s fingers crossed and a lot of time on the phone.
Experimental Vaccine Made From Frozen Immune Cells Shows Promise For Prostate Cancer Patients
Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it, according to data being presented by researchers from the Kimmel Cancer Center at Jefferson at the 2011 American Society of Clinical Oncology annual meeting in Chicago on Saturday, June 4…
Read more on Medical News Today
Fertility in cancer patients on new app, website
The Associated Press The Associated Press CHICAGO A new website and iPhone app aim to inform cancer patients and doctors about preserving fertility before treatment. Both were created by a consortium based at Northwestern University. The idea is to let newly diagnosed patients and their physicians know about things like freezing eggs, embryos and ovarian tissue, or banking sperm. These are among …
Read more on Washington Examiner
Cancer study yields hard facts
Ten years ago a Red Deer couple were among the first few thousand people to sign up for one of the largest medical research studies Alberta has ever conducted.
Read more on Red Deer Advocate
JVZoo Product Feed
Categories: News Tags: patient's, made, cancer, immune, cells, vaccine, prostate, frozen, experimental, shows
Cancer drug holds promise as first treatment for common, inherited dementia
Cancer drug holds promise as first treatment for common, inherited dementia
( UT Southwestern Medical Center ) A drug already approved for people with cancer shows early potential as a therapy for a common form of dementia, UT Southwestern Medical Center researchers report.
Read more on EurekAlert!
Expanding program would help those struggling with cancer
The North Platte Telegraph The American Cancer Society wants to expand a service that saves cancer patients money. Jill Koch, ACS community manager for the high plains division, presented information about the organization’s guest room program to the Lincoln County Tourism Advisory Council Wednesday.
Read more on North Platte Telegraph
JVZoo Product Feed
